Related Experiment Video
Updated: Mar 29, 2026
07:57
Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
7.2K
The Novel HSF1 Inhibitor NXP800 Exhibits Robust Antitumor Activity in Hepatocellular Carcinoma
Sara M Steinmann1,2, Melania Lazzari3,4,5, Augustinus Kleinle1
1Institute of Pathology, University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.
International Journal of Molecular Sciences
|March 28, 2026
Summary
NXP800, a novel Heat-shock factor 1 (HSF1) inhibitor, effectively reduces hepatocellular carcinoma (HCC) growth by inhibiting proliferation and inducing apoptosis. This agent shows promise as a potential therapeutic for HCC.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Heat-shock factor 1 (HSF1) overexpression is linked to hepatocellular carcinoma (HCC) development and progression.
- Targeting HSF1 is a potential therapeutic strategy for HCC.
Purpose of the Study:
- To investigate the antitumor activity of the HSF1 inhibitor NXP800 against HCC.
- To elucidate the metabolic and molecular mechanisms underlying NXP800's effects on HCC.
Main Methods:
- In vitro studies using human HCC cell lines.
- Assessment of cell proliferation, apoptosis, and DNA damage.
- Metabolic assays including mitochondrial respiration and glycolysis measurements.
- Molecular analysis of integrated stress response and E2F1 signaling.
- In vivo studies using HCC patient-derived organoids.
Main Results:
- NXP800 inhibited HCC cell proliferation, induced apoptosis, and caused DNA damage.
- NXP800 reduced mitochondrial respiration and glycolysis, with observed mitochondrial structural alterations.
- NXP800 upregulated the integrated stress response and downregulated E2F1 signaling.
- NXP800 demonstrated significant antitumor activity in HCC patient-derived organoids.
- Combination therapy with doxorubicin or olaparib enhanced NXP800's efficacy.
Conclusions:
- NXP800 exhibits significant antitumor activity against HCC through multiple mechanisms.
- NXP800 demonstrates potential as a therapeutic agent for HCC, particularly in combination therapies.
